SC
PCRX icon

Samlyn Capital’s Pacira BioSciences PCRX Stock Holding History

Samlyn Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-372,269
Closed -$14M – 146
2017
Q3 		$14M Buy
+372,269
New +$15M 0.35% 80
2017
Q1 		– Sell
-127,000
Closed -$4.1M – 158
2016
Q4 		$4.1M Buy
+127,000
New +$4.24M 0.09% 108

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Samlyn Capital's PCRX Position: Q4 2017 in Review

Samlyn Capital sold out of Pacira BioSciences (PCRX) in Q4 2017, closing a stake of 372,269 shares — an estimated $14M sold.

Samlyn Capital first reported a position in PCRX in Q4 2016 and held it in 2 quarters. The position peaked at $14M in Q3 2017. 185 funds tracked by Wall St. Rank hold PCRX as of Q4 2017.

  • Samlyn Capital reported no remaining Pacira BioSciences position as of Q4 2017 after selling out during the quarter.
  • Samlyn Capital sold 372,269 Pacira BioSciences shares in Q4 2017, an estimated $14M.
  • Samlyn Capital first reported a position in Pacira BioSciences in Q4 2016 and held it in 2 quarters.
  • Samlyn Capital's Pacira BioSciences position peaked at $14M in Q3 2017.
  • 185 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2017.

Based on Samlyn Capital's 13F filing for Q4 2017, filed 14 Feb 2018.